MedDataX Logo

TMC435-TiDP16-C108 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Digoxin and Between TMC435 and Rosuvastatin

NCT ID: NCT01288742

Last Updated: 2012-11-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

33 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-01-31

Study Completion Date

2011-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate the effect of steady-state concentrations of TMC435 on the single-dose pharmacokinetics of digoxin or rosuvastatin , and the effect of a single dose of digoxin or rosuvastatin on the steady-state pharmacokinetics of TMC435. Steady state is a term that means that the drug has been given long enough so that the plasma concentrations will remain the same with each subsequent dose. TMC435 is being investigated for the treatment of chronic hepatitis C virus (HCV) infection. Pharmacokinetics (PK) means how the drug is absorbed into the bloodstream, distributed in the body, and eliminated from the body.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

TMC435 is being investigated for treatment of chronic hepatitis C virus (HCV) infection, in combination with Peg-IFN (pegylated interferon) and RBV (ribavirin). Digoxin and rosuvastatin are expressed in the liver and intestine and mediate the transport of drugs out of the blood circulation. The result of this study will provide dosing recommendations for TMC435 and for digoxin, rosuvastatin, or other substrates using the same drug transporter molecules, when being coadministered. This is a Phase I, open-label (both participant and investigator know the name of the medication given at certain moment), randomized (sequence of treatment with study medications is assigned by chance), crossover trial in 32 healthy volunteers to investigate the pharmacokinetic interaction between TMC435, at steady state, and digoxin or rosuvastatin at a single dose. The volunteers will be allocated to one of two panels. In Panel 1, volunteers will receive two treatments (Trts A and B) in a randomized order. Volunteers will receive digoxin 0.25 mg once daily for 1 day (Trt A) and TMC435 150 mg once daily for 7 days (Trt B) and 0.25 mg digoxin once daily for 1 day (Trt B). In Panel 2, volunteers will receive two treatments (Trts C and D) in a randomized order. Volunteers will receive rosuvastatin 10 mg once daily for 1 day (Trt C) and TMC435 150 mg once daily for 7 days (Trt D) and rosuvastatin 10 mg once daily for 1 day (Trt D). In both panels, there will be a washout period (a period when no study drug will be taken, in order to have all the medication eliminated from the body before starting a new treatment) of at least 14 days between last intake of the study medication in one session and the first intake of study medication in the subsequent session. Pharmacokinetic profiles of all three compounds will be determined through blood samples taken at regular intervals during the study. Safety and tolerability will be assessed during the study period and during follow up. Blood and urine samples, electrocardiogram (ECG) and vital signs (blood pressure and heart rate) will be taken at screening, before medication intake on Day -1 or Day 1 (Trts A, B, C, and D), on Day 2 (Trts A and C), before medication intake and 6 hours postdose (only vital signs and ECG) on Day 7 (Trts B and D), on Day 8 (Trts B and D) and at the 2 follow up visits at 1 week and 4-5 weeks after last dose of study medication in the last session. A physical examination will be performed at screening, on Day -1 (= day before first medication intake in each session for both panels) and on Day 2 in Trts A and C, on Day -1 and on Day 8 of Trts B and D and during the 2 follow-up visits. Each volunteer is part of one panel and follows 2 treatment (Trt) periods, which are a minimum 14 days apart from each other. Trt period for Trts A and C - 5 days; Trt period for Trts B and D - 11 days. Trt A and B = Panel 1, Trt C and D = Panel 2. A single, oral dose of digoxin (0.25 mg) or rosuvastatin (10 mg) to be given in Trt A or Trt C, respectively. Multiple doses of TMC435 (150 mg) for 7 days to be given in TrtB and D, with a single dose of digoxin or rosuvastatin on Day7, respectively.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis C Virus

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

TMC435-TiDP16-C108 TMC435-C108 TMC435 HPC HCV Hepatitis C

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

001

TMC435 One 150-mg capsule once daily for 7 days (Trts B and D).

Group Type EXPERIMENTAL

TMC435

Intervention Type DRUG

One 150-mg capsule once daily for 7 days (Trts B and D).

002

Digoxin One 0.25-mg tablet for 1 day (Trt A)

Group Type EXPERIMENTAL

Digoxin

Intervention Type DRUG

One 0.25-mg tablet for 1 day (Trt A)

003

Digoxin One 0.25-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt B.

Group Type EXPERIMENTAL

Digoxin

Intervention Type DRUG

One 0.25-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt B.

004

Rosuvastatin One 10-mg tablet for 1 day (Trt C).

Group Type EXPERIMENTAL

Rosuvastatin

Intervention Type DRUG

One 10-mg tablet for 1 day (Trt C).

005

Rosuvastatin One 10-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt D.

Group Type EXPERIMENTAL

Rosuvastatin

Intervention Type DRUG

One 10-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt D.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rosuvastatin

One 10-mg tablet for 1 day (Trt C).

Intervention Type DRUG

Rosuvastatin

One 10-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt D.

Intervention Type DRUG

TMC435

One 150-mg capsule once daily for 7 days (Trts B and D).

Intervention Type DRUG

Digoxin

One 0.25-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt B.

Intervention Type DRUG

Digoxin

One 0.25-mg tablet for 1 day (Trt A)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Non-smoker or not having chewed tobacco for at least 6 months
* Body Mass Index of 18.0 to 30.0 kg/m2
* Healthy based on a medical evaluation including medical history, physical examination, blood tests, vital signs, and electrocardiogram

Exclusion Criteria

* Infection with hepatitis A, B or C virus
* Infection with the human immunodeficiency virus (HIV)
* History of, or any current medical condition which could impact the safety of the participant in the study
* Having previously participated in a multiple-dose trial with TMC435
* Having previously participated in more than 3 single-dose trials with TMC435
* History of rhabdomyolysis or other muscle abnormalities upon statin intake (Panel 2).
Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tibotec Pharmaceuticals, Ireland

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Tibotec Pharmaceuticals Clinical Trial

Role: STUDY_DIRECTOR

Tibotec Pharmaceutical Limited

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TMC435-TiDP16-C108

Identifier Type: -

Identifier Source: secondary_id

CR017770

Identifier Type: -

Identifier Source: org_study_id